|
Jul 31
|
Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
|
|
Jul 23
|
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
|
|
Jul 20
|
H.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX)
|
|
Jul 18
|
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)
|
|
Jun 30
|
While institutions own 28% of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), private equity firms are its largest shareholders with 48% ownership
|
|
Jun 23
|
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)
|
|
Apr 2
|
LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?
|
|
Apr 2
|
Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
|
|
Feb 18
|
Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)
|
|
Jan 21
|
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain
|
|
Jan 2
|
Lexicon Appoints Scott Coiante as Chief Financial Officer
|
|
Dec 30
|
Private equity firms account for 47% of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) ownership, while institutions account for 33%
|
|
Sep 27
|
Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress
|
|
Sep 10
|
New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes
|
|
Aug 28
|
Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More
|
|
Jul 25
|
Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024
|
|
Jun 21
|
Sector Update: Health Care Stocks Gain in Late Afternoon
|
|
Jun 21
|
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
|
|
Jun 18
|
Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology
|
|
Jun 14
|
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
|